Experimental pill targets Hard-to-Treat cancers with genetic flaw
Disease control
Terminated
This study tested an experimental drug called TNG908 in people with advanced solid tumors that lack a gene called MTAP. The drug works by blocking a protein that these cancer cells need to grow. The trial aimed to find the safest dose and see if the drug could shrink tumors, but …
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC